SGLT2 inhibitors reduce glycated hemoglobin (HbA1c) without raising hypoglycemia risk, also they can lose weight and improve hyperuricemia, blood lipids and blood pressure [8]. Here, SLC5A2 is linked to Hypoglycemia.